Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBITDA Margin (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed EBITDA Margin for 3 consecutive years, with 26.93% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 443.0% to 26.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7.46% through Dec 2025, up 821.0% year-over-year, with the annual reading at 7.46% for FY2025, 821.0% up from the prior year.
  • EBITDA Margin hit 26.93% in Q4 2025 for Immunocore Holdings, down from 3.44% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 14.93% in Q3 2024 to a low of 33.39% in Q1 2024.
  • Historically, EBITDA Margin has averaged 12.81% across 3 years, with a median of 15.65% in 2023.
  • Biggest five-year swings in EBITDA Margin: tumbled -3055bps in 2024 and later surged 3945bps in 2025.
  • Year by year, EBITDA Margin stood at 0.82% in 2023, then plummeted by -3747bps to 31.36% in 2024, then rose by 14bps to 26.93% in 2025.
  • Business Quant data shows EBITDA Margin for IMCR at 26.93% in Q4 2025, 3.44% in Q3 2025, and 3.9% in Q2 2025.